D
Lisata Therapeutics, Inc. LSTA
$4.59 $0.040.88% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$4.55
Volume
77,256
Avg Vol (90D)
140,791
Market Cap
$40.13M
Dividend & Yield
--
52-Week Range
$1.81 - $4.89
P/E (TTM)
--
EPS (TTM)
-$2.13
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
2/12/2026 - PR Newswire
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
2/12/2026 - PR Newswire
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update
2/4/2026 - Ticker Report
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm's Investigations
2/2/2026 - Globe Newswire
Short Interest in Lisata Therapeutics, Inc. (NASDAQ:LSTA) Drops By 16.3%
2/2/2026 - Zolmax
Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
1/29/2026 - Globe Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Reminds $hareholders of Upcoming Merger Deadlines PEN, RAPT, NATH, and LSTA
1/29/2026 - Globe Newswire
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
1/28/2026 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA
1/28/2026 - PR Newswire
Halper Sadeh LLC Encourages SKYT, NATH, LSTA Shareholders to Contact the Firm to Discuss Their Rights
1/27/2026 - Globe Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger PEN, RAPT, NATH, and LSTA
1/27/2026 - Globe Newswire
Lisata Therapeutics ends Qilu certepetide collaboration deal
1/27/2026 - TipRanks Financial Blog
Lisata Therapeutics (LSTA) Ends Licensing Agreement with Qilu Pharmaceutical
1/27/2026 - GuruFocus
Lisata regains China rights to pancreatic cancer drug
1/27/2026 - Proactive Investors - UK
Lisata Therapeutics announces mutual termination of license agreement with Qilu
1/27/2026 - The Fly
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical ...
1/27/2026 - GuruFocus
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
1/27/2026 - Globe Newswire
lisata reclaims china rights solid tumor candidate ahead acquisition
1/27/2026 - FierceBiotech.com - Biotech
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching
1/22/2026 - Simply Wall St
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, ...
1/21/2026 - GuruFocus
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
1/21/2026 - Business Wire
Market movers: Kraft Heinz, Lisata Therapeutics, Halliburton, Johnson & Johnson...
1/21/2026 - Proactive Investors - UK
Lisata Therapeutics (LSTA) Downgraded by Brookline Capital LSTA Stock News
1/21/2026 - GuruFocus
Why Is Lisata Therapeutics Stock Gaining Today?
1/21/2026 - Benzinga
Lisata Therapeutics Agrees to All-Cash Acquisition by Kuva
1/21/2026 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$1.07M
EBITDA (TTM)
-$19.91M
EBIT (TTM)
-$20.08M
Net Income (TTM)
-$18.24M
Balance Sheet
Total Assets (Q)
$21.76M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$4.64M
Book Value Per Share (Q)
$1.98
Cash Flow
Cash from Operations (TTM)
-$17.23M
Cash from Investing (TTM)
$16.48M
Cash from Financing (TTM)
$298.00K
Net Change in Cash (TTM)
-$511.00K
Filings
Filing Date
Thursday, November 6, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
0.41
7-Day Total Return
-2.55%
30-Day Total Return
146.77%
60-Day Total Return
119.62%
90-Day Total Return
82.87%
Year to Date Total Return
134.18%
1-Year Total Return
75.19%
2-Year Total Return
66.61%
3-Year Total Return
35.80%
5-Year Total Return
-87.46%
52-week Low
Nov 21, 2025 - $1.81
52-week High
Jan 27, 2026 - $4.89
Valuation
Market Cap
$40.13M - Nano Cap
Enterprise Value
$20.88M
Price/Sales (TTM)
37.17
Price/Book (Q)
2.29
Dividends and Shares
Shares Outstanding
8.74M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.lisata.com
Phone Number
908 842 0100
Address
110 Allen Road
Basking Ridge, NJ 07920
Country
United States
Year Founded
1980
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases... more
NASDAQ 02/13/2026 1:00PM Eastern Quotes delayed